Human dermal fibroblasts - SpinalCyte

Drug Profile

Human dermal fibroblasts - SpinalCyte

Alternative Names: CybroCell; CybroCell Human Dermal Fibroblasts

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SpinalCyte
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Intervertebral disc degeneration

Most Recent Events

  • 12 Apr 2018 SpinalCyte files an IND application with the US FDA to expand phase I/II trial for Intervertebral disc degeneration (In adults, In the elderly)
  • 03 Apr 2018 Interim efficacy data from a phase I/II trial in Intervertebral disc degeneration released by SpinalCyte
  • 13 Feb 2018 Positive efficacy data from a phase I/II trial in Intervertebral disc degeneration released by SpinalCyte
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top